(Q30885891)

27 June 2017

title

Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. (English)

1 reference

27 June 2017

1

Gary V Doern

1 reference

27 June 2017

Steve D Brown

2

1 reference

27 June 2017

publication date

1 January 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

48

1 reference

27 June 2017

issue

1

1 reference

27 June 2017

page(s)

56-65

1 reference

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Community-acquired lower respiratory tract infections: etiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Fluoroquinolone resistance in Streptococcus pyogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-4453%2803%2900123-3

7 January 2021

10.1016/S0163-4453(03)00123-3

Identifiers

DOI

1 reference

27 June 2017

1 reference